logo-loader
RNS
viewTissue Regenix Group PLC

Tissue Regenix Group - Option Exercise and Total Voting Rights

RNS Number : 8323Q
Tissue Regenix Group PLC
23 June 2020
 

Tissue Regenix Group Plc

("Tissue Regenix" or the "Company")

PDMR dealing and issue of equity

Leeds, 23 June 2020- Tissue Regenix Group plc (AIM:TRX), the regenerative medical devices company, announces the exercise of options by Shervanthi Homer-Vanniasinkam, a Non-Executive Director.

In consequence of the exercise of options, the Company has issued and allotted 1,388,222 ordinary shares of 0.1p each in the Company (the "Option Shares") at an exercise price of 0.00456p pence per share. The Option Shares will rank pari passu with the existing ordinary shares. An application has been made for the Option Shares to be admitted to trading on AIM which is expected to take place at 8:00am on or around 29 June 2020.

Following the issue of the Option Shares, Ms Homer-Vanniasinkam will be interested in a total of 1,638,222 shares in the Company representing 0.02% of the enlarged issued share capital.

Total voting rights

Following the issue of the 1,388,222 new ordinary shares, the Company will have a total of 7,032,985,756 ordinary shares of 0.1p each in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

For more Information:

Tissue Regenix Group plc

Caitlin Pearson, Head of Communications  

 

Tel: 0330 430 3073

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Jonathan Senior / Alex Price / Ben Maddison

Tel:  0207 710 7600

 

 

 

FTI Consulting 

Simon Conway / Victoria Foster Mitchell / Mary Whittow

Tel: 0203 727 1000

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

 

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

   1

 

Details of the person discharging managerial responsibilities / person closely associated  

a)

 

Names 

Shervanthi Homer-Vanniasinkam

2

 

Reason for the notification

a)

 

Position/status

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a)

 

Name

 

Tissue Regenix Group plc

b)

 

LEI

 213800PNOD5UHQUFJI36

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Ordinary Shares of 0.1p

b)

Identification code 

 

GB00B5SGVL29

c)

 

Nature of the transaction 

 

Exercise of options over Ordinary Shares

d)

 

Price(s) and volume(s)

Volume(s):

1,388,222 Ordinary Shares

Price: 0.00456 pence per Ordinary Share

d)

 

Aggregated information 

- Aggregated volume

- Price

N/A

 

e)

 

Date of the transactions 

23 June 2020

f)

 

Place of the transaction

Outside of a trading venue

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHFJMJTMTATBIM

Quick facts: Tissue Regenix Group PLC

Price: 0.3019

Market: AIM
Market Cap: £21.23 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016